ストックスクリーナーアプリを入手
28.74
8.82%
2.33
前日終値:
$26.41
開ける：
$26.93
24時間の取引高:
2.25M
Relative Volume:
1.16
時価総額：
$3.61B
収益：
$415.62M
当期純損益:
$-2.38M
株価収益率:
-1,011.97
EPS:
-0.0284
ネットキャッシュフロー:
$16.92M
1週間 パフォーマンス:
+17.35%
1か月 パフォーマンス:
+22.25%
6か月 パフォーマンス:
+16.92%
1年 パフォーマンス:
+32.87%
1日の値動き範囲:
$26.93
$28.96
1週間の範囲:
$24.30
$26.97
52週間の値動き範囲:
$19.30
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
名前
Arcutis Biotherapeutics Inc
セクター
電話
805-418-5006
住所
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
28.74 | 3.61B | 415.62M | -2.38M | 16.92M | -0.0284 |
VRTX
Vertex Pharmaceuticals Inc
|
509.10 | 129.04B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.23 | 95.11B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.96 | 82.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
847.89 | 53.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.80 | 42.06B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | 開始されました | Goldman | Neutral |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-28 | 開始されました | Jefferies | Buy |
| 2024-01-03 | アップグレード | Mizuho | Neutral → Buy |
| 2023-10-26 | ダウングレード | Mizuho | Buy → Neutral |
| 2023-10-13 | ダウングレード | Goldman | Buy → Neutral |
| 2022-09-07 | 開始されました | Needham | Buy |
| 2022-03-17 | 開始されました | Goldman | Buy |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-05-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | アップグレード | Goldman | Neutral → Buy |
| 2020-10-08 | 開始されました | Truist | Buy |
| 2020-02-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 開始されました | Cowen | Outperform |
| 2020-02-25 | 開始されました | Goldman | Neutral |
| 2020-02-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Arcutis Biotherapeutics Inc (ARQT) 最新ニュース
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical - GlobeNewswire Inc.
An iShares ETF has an interest above 5% in Arcutis (ARQT), where BlackRock reports a passive stake. - Stock Titan
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares - Investing.com
Arcutis Biotherapeutics director Welgus sells $114k in shares By Investing.com - Investing.com India
Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11% - TIKR.com
Arcutis Biotherapeutics director Welgus sells $114k in shares - Investing.com
Former Arcutis (NASDAQ: ARQT) officer plans multimillion-dollar stock sale - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) director plans $114K stock sale - Stock Titan
Arcutis EVP, Chief Legal Officer Masaru Matsuda sells 9,989 shares for $249,861 - Bitget
Arcutis Biotherapeutics (ARQT) Insider Masaru Matsuda Sells 9,98 - GuruFocus
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock - investing.com
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock By Investing.com - Investing.com Canada
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock - Investing.com
Arcutis (ARQT) officer lines up Rule 144 stock sale - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals - ChartMill
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70%SNS Insider - GlobeNewswire Inc.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
(ARQT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - manilatimes.net
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - Barchart.com
ARQT Stock Price, Quote & News - Syfe
Arcutis director Terrie Curran sells $956k in shares By Investing.com - Investing.com Nigeria
Arcutis director Terrie Curran sells $956k in shares By Investing.com - Investing.com Canada
Arcutis director Terrie Curran sells $956k in shares - Investing.com
Here's Why You Should Add ARQT Stock to Your Portfolio Now - theglobeandmail.com
Here's Why You Should Add ARQT Stock to Your Portfolio Now - TradingView
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Arcutis (NASDAQ: ARQT) insider plans $956K share sale - Stock Titan
Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18K - benzinga.com
Arcutis Biotherapeutics Director Terrie Curran Executes Stock Option and Sells Shares on August 20, 2026 - Kalkine Media
Arcutis Biotherapeutics CMO Patrick Burnett Sells Shares to Cover Tax Withholding on RSU Vesting - Kalkine Media
Tejara Capital Ltd Buys Shares of 113,084 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Polar Capital Holdings Plc Buys Arcutis Biotherapeutics Inc (ARQ - GuruFocus
Arcutis (NASDAQ: ARQT) director to sell 1,072 shares - Stock Titan
ARQT Looks 18.5% Undervalued on GF Value™ After Health Canada Ap - GuruFocus
PrZORYVE® Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic Dermatitis - PR Newswire Canada
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,730 Shares - MarketBeat
Arcutis (NASDAQ: ARQT) officer to sell 1,697 shares after recent August trades - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup - ChartMill
Arcutis (ARQT) Q2 2026 Earnings: EPS Beats Its Estimate in Latest Trading; Shares After the Report: The Stock Ends Up 3.63% at the CloseSegment Revenue Breakdown - Vinanet
Arcutis (NASDAQ: ARQT) holder plans $123,834 August sale - Stock Titan
Arcutis (ARQT) Q2 2026 Earnings Call Transcript - AOL.com
Arcutis Biotherapeutics (ARQT) Gains 1.39% as Shares Push Toward Key ResistanceSupport Level Bounce - Vinanet
Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action? - webull.com
Liquidity Mapping Around (ARQT) Price Events - Stock Traders Daily
Arcutis Biotherapeutics Inc (ARQT) 財務データ
収益
当期純利益
現金流量
EPS
Arcutis Biotherapeutics Inc (ARQT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Larry Todd Edwards | Former Officer |
Sep 16 '26 |
Proposed Sale |
25.00 |
341,980 |
8,549,500 |
0 |
| Welgus Howard G. | Director |
Sep 15 '26 |
Sale |
24.18 |
4,730 |
114,371 |
35,841 |
| Howard Welgus | Director |
Sep 15 '26 |
Proposed Sale |
24.18 |
4,730 |
114,371 |
0 |
| Welgus Howard G. | Director |
Sep 15 '26 |
Option Exercise |
7.93 |
4,096 |
32,475 |
40,571 |
| Masaru Matsuda | Officer |
Sep 08 '26 |
Proposed Sale |
25.03 |
13,663 |
341,933 |
0 |
| Matsuda Masaru | See Remarks |
Sep 08 '26 |
Sale |
25.03 |
9,989 |
249,986 |
116,182 |
| Terrie Curran | Director |
Aug 27 '26 |
Proposed Sale |
25.03 |
38,200 |
956,125 |
0 |
| Curran Terrie | Director |
Aug 27 '26 |
Option Exercise |
8.30 |
38,200 |
317,180 |
50,578 |
| Curran Terrie | Director |
Aug 27 '26 |
Sale |
25.03 |
38,200 |
956,123 |
23,526 |
| Curran Terrie | Director |
Aug 20 '26 |
Option Exercise |
7.51 |
1,072 |
8,051 |
24,598 |
1.13%
0.20%
大文字化:
|
ボリューム (24 時間):